Protalix BioTherapeutics,
Inc. PLX announced today that the first patient has
been treated in the Company's phase I clinical trial of PRX-112, or Oral GCD,
the Company's orally-administered enzyme product candidate for the treatment
of Gaucher disease. Oral GCD is a plant cell expressed form of the
glucocerebrosidase enzyme (GCD) that is naturally encapsulated within carrot
cells and administered orally. Protalix expects the phase I trial to be
completed during the third quarter of 2013.
"With Oral GCD, we are using the natural characteristics of plant cells to
deliver active enzyme into the patient's blood stream," said Professor Ari
Zimran, M.D., Director of the Gaucher Clinic in Shaare Zedek Medical Center,
Jerusalem, Israel and lead clinical investigator. "We believe oral delivery of
GCD has the potential to improve patients' quality of life without
compromising the efficacy or safety of the treatment."
The phase I clinical trial is an open label safety and pharmacokinetic study
designed to assess the delivery of prGCD after oral administration of Oral GCD
in 12 Gaucher patients. Subjects receive re-suspended carrot cells in a single
oral administration during the first cohort of the trial and three consecutive
daily administrations during the second cohort of the trial.
Pre-clinical studies of oral GCD demonstrate the stability of the enzyme in
the carrot cell and the capacity of the cell's cellulose wall to protect the
enzyme against degradation in the digestive tract in an in-vitro model of the
stomach and intestines. Additionally, both rats and pigs fed with PRX-112,
lyophilized carrot cells expressing GCD, have demonstrated enzyme levels in
the plasma and accumulation of the active enzyme in target organs such as the
spleen and liver.
Dr Einat Brill Almon, the Company's Senior Vice President, Product
Development, added: "We successfully demonstrated the ability of plant cells
to act as an oral delivery mechanism for a number of therapeutic proteins in
our animal studies. We believe that the results of our clinical trial of Oral
GCD will provide additional support for our belief that this oral delivery
mechanism can be developed for other proteins used to treat other
indications."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in